Drugs Management Programme
COVID 19 Information
Interim Recommendations for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation
Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19)
Acute Hospitals Drugs Management Programme
The Acute Hospitals Drugs Management Programme (AHDMP) is one of three strands of the National Drugs Management Programme (NDMP). The NDMP was established in 2016 to promote the cost-effective use of medicines and to provide equitable access to drug therapies on the basis of clinical need in the Irish Health Service.
The AHDMP is responsible for:
- Coordinating and supporting medicine management initiatives within the acute hospital setting;
- Ensuring the full benefits of the 2016 IPHA (Irish Pharmaceutical Healthcare Association) Agreement for acute hospital services are realised effectively in the best interests of patients and services;
- Enabling good systems of internal controls around the design, implementation and maintenance of pharmacy data management;
- Minimising the on-going workload for key stakeholders associated with medicine management i.e. hospital groups and individual hospital pharmacist leads, suppliers, Acute Hospital Division, Corporate Finance Division; HSE Health Business Service (HBS), Finance, CPU and;
- Maximising the opportunities for improved transparency around pricing, volume and cost of drugs and medicine using data analytics and engagement with pharmacy and procurement leads.
For all queries please contact: AHDMP@hse.ie
National Drugs Management Scheme:
The National Drugs Management Scheme (NDMS) is a web-based, centralised reimbursement system for high-cost drugs. This scheme is now in place within our acute hospitals for the purchase and provision of the approved drugs Natalizumab (Tysabri) and Alemtuzumab (Lemtrada) for Multiple Sclerosis (MS). For more information see the National Drugs Management Scheme.